Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles Congreve

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Angewandte Chemie (International Ed. in English)|June 17, 2020
X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A<sub>2A</sub> Adenosine Receptor AntagonistsWillem Jespers, Grégory Verdon, Jhonny Azuaje, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 1, 2022
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M<sub>1</sub> receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's diseasePradeep J Nathan, S Babli Millais, Alex Godwood, et al.
British Journal of Clinical Pharmacology|December 22, 2020
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub> -receptor partial agonist for the treatment of dementiasCharlotte Bakker, Tim Tasker, Jan Liptrot, et al.
Nature|June 1, 2017
Crystal structure of the GLP-1 receptor bound to a peptide agonistAli Jazayeri, Mathieu Rappas, Alastair J H Brown, et al.
Nature|July 13, 2017
Corrigendum: Crystal structure of the GLP-1 receptor bound to a peptide agonistAli Jazayeri, Mathieu Rappas, Alastair J H Brown, et al.
Journal of Medicinal Chemistry|August 20, 2010
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiencyChristopher W Murray, Maria G Carr, Owen Callaghan, et al.
Journal of Medicinal Chemistry|June 20, 2020
Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of MigraineSarah J Bucknell, Mark A Ator, Alastair J H Brown, et al.
Journal of Medicinal Chemistry|November 8, 2007
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiencyPhilip D Edwards, Jeffrey S Albert, Mark Sylvester, et al.
Journal of Medicinal Chemistry|December 21, 2019
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational AnalysisMathieu Rappas, Ammar A E Ali, Kirstie A Bennett, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Angewandte Chemie (International Ed. in English)|June 17, 2020
X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A<sub>2A</sub> Adenosine Receptor AntagonistsWillem Jespers, Grégory Verdon, Jhonny Azuaje, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 1, 2022
A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M<sub>1</sub> receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's diseasePradeep J Nathan, S Babli Millais, Alex Godwood, et al.
British Journal of Clinical Pharmacology|December 22, 2020
First-in-man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M<sub>1</sub> -receptor partial agonist for the treatment of dementiasCharlotte Bakker, Tim Tasker, Jan Liptrot, et al.
Nature|June 1, 2017
Crystal structure of the GLP-1 receptor bound to a peptide agonistAli Jazayeri, Mathieu Rappas, Alastair J H Brown, et al.
Nature|July 13, 2017
Corrigendum: Crystal structure of the GLP-1 receptor bound to a peptide agonistAli Jazayeri, Mathieu Rappas, Alastair J H Brown, et al.
Journal of Medicinal Chemistry|August 20, 2010
Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiencyChristopher W Murray, Maria G Carr, Owen Callaghan, et al.
Journal of Medicinal Chemistry|June 20, 2020
Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of MigraineSarah J Bucknell, Mark A Ator, Alastair J H Brown, et al.
Journal of Medicinal Chemistry|November 8, 2007
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiencyPhilip D Edwards, Jeffrey S Albert, Mark Sylvester, et al.
Journal of Medicinal Chemistry|December 21, 2019
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational AnalysisMathieu Rappas, Ammar A E Ali, Kirstie A Bennett, et al.
Journal for Immunotherapy of Cancer|July 31, 2020
Small molecule AZD4635 inhibitor of A<sub>2A</sub>R signaling rescues immune cell function including CD103<sup>+</sup> dendritic cells enhancing anti-tumor immunityAlexandra Borodovsky, Christine M Barbon, Yanjun Wang, et al.
Pageof 6